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Abstract 
Methylation of DNA is known to be essential to development and dramatically altered in 
cancers. The Illumina HumanMethylation450 BeadChip has been used extensively as a cost-
effective way to profile nearly half a million CpG sites across the human genome. Here we 
present DiffVar, a novel method to test for differential variability between sample groups. 
DiffVar employs an empirical Bayes model framework that can take into account any 
experimental design and is robust to outliers. We applied DiffVar to several datasets from 
The Cancer Genome Atlas, as well as an aging dataset. DiffVar is available in the missMethyl 
Bioconductor R package. 
Background 
DNA methylation is crucial for normal embryonic development with roughly 3-6% of all 
cytosines methylated in normal human DNA [1]. However, methylation changes are known 
to accumulate with age [2], with up to 30% of CpG sites changing methylation status within 
the first 1.5 years of life [3]. In addition, aberrant methylation patterning is associated with 
many diseases. In particular, in cancer cells, disruption of normal methylation events are very 
common with the number of genes undergoing CpG island promoter hypermethylation 
increasing during tumour development, combined with an extensive loss of DNA methylation 
in other genomic regions [1,4]. This phenomenon is not consistent across all cancers 
however; distinct DNA methylation patterns have been observed between sub-types of the 
same cancer [5-7]. Akalin et al. [5] show that one sub-type of Acute Myeloid Leukemia 
shows widespread hypermethylation in promoter regions and CpG islands neighbouring the 
transcription start site of genes, while a second sub-type displayed extensive loss of 
methylation at an almost mutually exclusive set of CpGs in introns and intergenic CpG 
islands and shores. Abnormal methylation events can potentially silence tumour suppressor or 
growth regulatory genes, activating novel pathways that contribute to tumour progression [8]. 
However, epigenetic changes are potentially reversible, as it is possible to reactivate genes 
that have been silenced by methylation [1], making them an attractive therapeutic target. 
Hence the study of DNA methylation in cancer remains an important topic of interest with 
much still to be discovered. 
Cancer is a heterogeneous disease. Within each type of cancer there is the potential for 
tumour growth to be driven by perturbations in many different molecular pathways, and these 
perturbations will vary from individual to individual. Epigenetic instability or the loss of 
epigenetic control of important genomic domains can lead to increased methylation 
variability in cancer, which may contribute to tumour heterogeneity [9]. In a large study 
profiling 1505 CpG sites of 1628 human samples, of which 1054 were tumours, Fernandez et 
al. [10] observed little variation in the DNA methylation patterns of normal tissue, while the 
established tumours showed greater CpG methylation heterogeneity. Hansen et al. [9] 
propose that increased epigenetic heterogeneity in cancer could underlie the ability of cancer 
cells to adapt rapidly to changing environments. Hence studying the heterogeneity of cancers 
could lead to better understanding of tumourigenesis. 
As mentioned, it has been shown that DNA methylation patterns are associated with an 
individuals’ age [2]. Interestingly, both tumour development and aging are processes which 
result in the global loss of genome wide DNA methylation combined with gains in CpG 
island promoter methylation [11,12]. Hence it has been speculated that the accumulation of 
epigenetic alterations during aging might contribute to tumourigenesis [12]. 
Several technologies are available for profiling DNA methylation, both array and sequencing 
based. While the cost of next generation sequencing has dramatically decreased, it is still too 
expensive for many large studies to profile widespread methylation. The introduction of the 
Illumina 450 K human methylation array is a more affordable alternative for measuring 
genome-wide DNA methylation at 482,421 CpG sites. Consequently, thousands of tumour 
and normal tissues have been profiled using these arrays, with numerous cancer datasets now 
publicly available through The Cancer Genome Atlas (TCGA) [13,14]. Similarly, these 
arrays are being used to profile methylation differences between disease cases and normal 
controls in so called eigenome-wide association studies (EWAS) [15]. 
To date, the main focus when analysing DNA methylation data has been detecting CpG sites 
that are differentially methylated between groups. Methods to detect differences in means for 
high-dimensional biological data are well-established and include approaches such as those 
taken in the Bioconductor [16] software packages limma [17], minfi [18], edgeR [19] and 
DESeq [20]. A CpG site that is statistically significantly differentially methylated between 
groups (for example, cancer versus normal) will have different group means; however, the 
measurements within each group will tend to be quite consistent (Figure 1A). Recently, 
several papers have observed consistent methylation between normal samples and highly 
variable methylation between cancer samples, arguing that identifying features that differ in 
terms of variability may be just as relevant or important as differential methylation for 
understanding disease phenotypes [21-25]. In other words, there is interest in identifying 
differentially variable CpG sites, where the samples in one group have consistent methylation 
values and the samples in the other group have highly variable methylation values (Figure 
1B). 
Figure 1 Differential methylation (DM) and differential variability (DV) in the kidney 
cancer methylation dataset. The plots in (A) and (C) show the M values and absolute 
deviations of the most significant differentially methylated CpG site between the normal and 
cancer samples. There is an obvious shift in mean between cancer and normal (A), but from 
(C) the variability in both groups looks very similar. The plots in (B) and (D) show the M 
values and absolute deviations of the most significant differentially variable CpG site 
between the normal and cancer samples. It is clear that the variability of the cancer and 
normal groups are very different, with very large deviations in the cancer group and 
consistently small deviations in the normal group apparent in (D). 
Methods for detecting differential variability in high dimensional ‘omics data have not been 
well addressed in the literature to date. Jaffe et al. [24] have a sophisticated method to detect 
differential variability over regions, specifically developed for the CHARM array [26]. Bar et 
al. [27,28] propose a three component mixture model on the ratio of the sample variances 
from treatment and control groups. The method aims to separate features that are not 
differentially variable, have inflated variance in the treatment group, or inflated variance in 
the control group. In addition, they perform empirical Bayes shrinkage on the inflation 
factors to stabilise the estimates. Other attempts for determining CpG site-wise differential 
variability include the F-test [9,29] and the Bartlett test [25]. Unfortunately, the F-test and 
Bartlett test are known to be highly sensitive to outliers [30]. While Hansen et al. [9] do not 
address the issue of outliers in the data when using an F-test for equality of variances; Ho et 
al [29] perform an outlier removal step prior to testing for differential variability. By contrast, 
Teschendorff and Widschwendter [25] implement the Bartlett test and claim that features that 
are differentially variable due to outliers are of interest. Their application is specific to the 
early stages of carcinogenesis, where they hypothesised that outliers may play an important 
role. It has been observed, however, that outliers are often a result of technical and biological 
artefacts rather than being biologically relevant to disease. For example, a technical artefact 
could arise due to processes surrounding the technology and biological artefacts could 
include stromal contamination of a tumour sample. Microarrays can suffer from spatial 
artefacts [31] and outliers arising from sample specific GC content biases have been reported 
in RNA sequencing data [32]. Mislabelled samples can also lead to outlying observations 
[33]. Hence, a method that successfully identifies differentially variable sites with a broader 
distribution of methylation values, such as that in Figure 1B, is desirable. Furthermore, the F-
test and Bartlett test assume that the data is normally distributed, which is not the case for 
methylation data [34]. 
Here we present a new method for detecting differential variability for individual CpG sites 
in methylation data. Our approach is inspired by Levene’s z-test [35]. It is a simple and 
computationally efficient test that is robust against non-normality and outliers. A major 
advantage of our method is that it is suitable for any experimental design; it is not limited to a 
two-group scenario. The method, called DiffVar, is available as a function in the missMethyl 
Bioconductor R package, and depends on the limma framework. We applied DiffVar to 
several publicly available cancer datasets from TCGA, as well as a publicly available aging 
dataset [2]. When we applied DiffVar to the cancer data sets from TCGA we observed that a 
large proportion of the top differentially variable CpG sites are found in CpG islands. 
Interestingly, the top differentially variable CpG islands tend to differ from cancer to cancer. 
We further found that the 10,000 top ranked differentially variable CpG sites have very little 
overlap with the 10,000 top ranked differentially methylated CpG sites, consistent with the 
findings in Teschendorff and Widschwendter [25]. Applying DiffVar to an aging dataset 
revealed that the centenarians have highly variable methylation compared to newborns and 
approximately 17% of the differentially variable CpGs were also differentially methylated. 
Results 
DiffVar: a new method to identify differentially variable features 
The focus of this paper is on methylation data from Illumina’s Infinium 
HumanMethylation450 BeadChip, although our method can be applied to any high 
dimensional data such as gene expression data. The output from the array consists of two 
measurements for each CpG site, the methylated and unmethylated intensity signal. These 
two measurements can be used to calculate either β values, which capture the proportion of 
methylation at each CpG site, or M values, defined as the log2-ratio of the methylated to 
unmethylated intensity. Since M values do not display the severe heteroscedasticity that 
occur with β values [34], DiffVar is performed on M values. If only β values are available 
they can be transformed into M values using a logit transformation, M = logit(β). Similarly M 
values can be converted back to β values for interpretation and visualisation. For more details 
on the array and raw data see ‘Materials and Methods’. 
As mentioned, our method is inspired by Levene’s z-test [35]. Intuitively, a measure of 
variability can be thought of as the distance of each point within a group from the group 
mean. Figure 1C and D show examples of the CpG sites from Figure 1A and B across a large 
kidney cancer and normal dataset from TCGA (see ‘Materials and Methods’). Each sample is 
plotted as a bar with the height of the bar equal to the absolute deviation from the group 
mean. Highly variable groups will be characterised by consistently large deviations (Figure 
1D, red bars representing the cancer group) and low variability groups will have consistently 
small deviations (closer to zero) about the group mean (Figure 1D, blue bars representing the 
normal group). In order to determine if one group is more variable than another, we can 
simply perform a t-test on the absolute or squared deviations of the M values from the group 
mean. This tests the null hypothesis that the group variances are equal. CpG sites that have 
deviations consistently larger in one group compared to another group will be identified as 
significantly differentially variable. Figure 1C shows the absolute deviations from the group 
means for the top differentially methylated CpG site. Although there is a shift in mean M 
values between the two groups, the variations about the mean are similar in both groups; 
hence this CpG site will not be significantly differentially variable. 
In high dimensional data, it is well-known that a simple t-test can result in many false 
discoveries, hence we employ an empirical Bayes modelling framework to stabilise the t-
statistics [36]. Additional variables, which may influence the variability within groups, can be 
taken into account within the linear modelling framework. This ensures that any experiment 
that can be summarised by a design matrix can be accommodated. Unequal sample sizes are 
taken into account by multiplying the absolute or squared deviations from the group mean by 
a leverage factor, nk /(nk + 1), where nk is the sample size for group k. Moderated t statistics 
[36] are computed and Benjamini and Hochberg false discovery rates (FDR) [37] are 
reported. In this manner, a list of differentially variable CpG sites is obtained. For a more 
formal definition of the statistical model see the Additional file 1. 
Simulation study 
DiffVar correctly controls Type I error rate 
Two strategies were used to determine type I error rate control. The first strategy generated M 
values under a hierarchical model while the second strategy involved resampling data from 
the kidney cancer data set, using only the non-diseased samples. Details of the simulations 
are provided in ‘Materials and Methods’. Briefly, a two group scenario with a sample size of 
50 in each group was simulated. M values were generated for ten thousand CpG sites and 
with the same variance for each group. CpG sites were tested for differential variability using 
the F-test, Bartlett’s test, DiffVar with absolute deviations, and DiffVar with squared 
deviations. The numbers of significant raw p-values at cut-offs of 0.001, 0.01, 0.05 and 0.1 
were counted for each of 1000 simulations. Table 1 summarises the results. Under the 
hierarchical model, the type I error rates are very close to the nominal p-value for all tests, 
showing that all tests have good type I error rate control in this scenario, although DiffVar 
with squared deviations appears conservative at 0.001. For the resampled data, the Bartlett 
test and the F test lose type I error rate control for all nominal p-values (Table 1). This is 
likely due to real data containing technical and biological artefacts that produce outliers. By 
contrast, DiffVar with absolute and squared deviations maintains type I error rate control over 
all nominal p-values. DiffVar with squared deviations is conservative at nominal p-values of 
0.001 and 0.01. 
Table 1 Comparing the type I error rate for the four different methods 
Data generated under hierarchical model 
 Nominal P-value 
Test method 0.001 0.01 0.05 0.1 
Bartlett 0.001032 0.01014 0.0504 0.1006 
F test 0.001011 0.01003 0.05001 0.1001 
DiffVar (abs) 0.0010029 0.01023 0.05094 0.1036 
DiffVar (sq) 0.0007118 0.009800 0.0499 0.1018 
Resampled data from kidney non-diseased samples 
 Nominal P-value 
Test method 0.001 0.01 0.05 0.1 
Bartlett 0.009 0.0257 0.07715 0.1331 
F test 0.0089 0.0253 0.0763 0.1319 
DiffVar (abs) 0.001 0.0104 0.0523 0.105 
DiffVar (sq) 0.0004 0.00665 0.0448 0.0981 
Data was generated in two ways: under a hierarchical model, and by randomly selecting the 
non-diseased kidney samples. Median type I error rates are reported for 1000 simulations 
with no differentially variable or differentially methylated features. For simulations generated 
under the hierarchical model, the standard deviation with which the error rate is estimated 
ranges from approximately 0.00024 for rates near 0.001 to 0.0029 for rates near 0.1 with no 
notable difference between the methods. For the resampled data, the standard deviation 
ranges from approximately 0.0026 for rates near 0.001 to 0.026 for rates near 0.1 with 
DiffVar (sq) being noticeably less variable than the other methods. 
DiffVar is robust to outliers 
To further explore the effect of outliers, the simulations under the hierarchical model were 
modified to incorporate 200 CpGs with a single outlier by randomly selecting one sample and 
substituting the maximum M value over all ten thousand simulated M values. From Table 2 it 
is again apparent that the Bartlett and F-test are extremely sensitive to outliers and have lost 
all type I error rate control, particularly for smaller nominal p-values. DiffVar with absolute 
or squared deviations is robust to outliers and maintains type I error control, although DiffVar 
with squared deviations is once again conservative at nominal rates of 0.001 and 0.01. Figure 
2A shows the number of CpGs with outliers in the top 500 features ranked by each method. 
Although the F and Bartlett tests produce different p-values, they have similar ranking by p-
value, resulting in overlapping curves for Figure 2A and B. It is immediately apparent that 
the top ranked features by Bartlett and F p-values are produced by probes with outliers. In 
contrast, DiffVar using either squared or absolute deviations does not preferentially rank the 
CpG sites containing outliers near the top of the list (Figure 2A). 
Table 2 Comparing the type I error rate for the four different methods in the presence 
of 200 outliers 
 Nominal P-value 
Test method 0.001 0.01 0.05 0.1 
Bartlett 0.01379 0.02601 0.06781 0.1179 
F test 0.01467 0.02663 0.06767 0.1172 
DiffVar (abs) 0.0009701 0.01006 0.05085 0.1019 
DiffVar (sq) 0.0005373 0.008198 0.04880 0.1011 
Median type I error rates are reported for 1000 simulations with no differentially variable or 
differentially expressed features, but with 200 outliers incorporated in the data. The standard 
deviation with which the error rate is estimated ranges from approximately 0.0003 for rates 
near 0.001 to 0.003 for rates near 0.1 with the Bartlett and F test more variable than DiffVar 
at nominal p-values of 0.001 (sd approximately 0.002 compared to 0.0003) and 0.01 (sd 
approximately 0.0018 compared to 0.0010). 
Figure 2 Performance of the four different methods using simulations. Results shown in 
plots (A-D) are averaged over 1000 simulated datasets and results shown in plots (E-F) are 
averaged over 100 resampled datasets at each sample size. Plot (A) shows the cumulative 
numbers of differentially variable CpG probes containing outlier observations when ranking 
by the four different methods. There are no differentially variable CpGs simulated but 200 
outliers are included in the data. Plot (B) shows ROC curves when 200 outliers and 1000 
differentially variable CpGs are present in the simulated data. Plot (C) shows the control of 
the false discovery rate (FDR) of the four methods at a 5% nominal FDR cut-off (horizontal 
dashed black line) over ten different sample sizes. This simulation contains 1000 CpGs which 
are roughly five times more variable in Group 2 compared with Group 1. Plot (D) shows the 
power to detect differentially variable features at ten different sample sizes when Group 2 is 
roughly five times more variable than Group 1. Plot (E) shows the control of the FDR using 
resampled kidney cancer datasets at 11 different sample sizes. Plot (F) shows power to detect 
differentially variable features using resampled kidney cancer datasets at 11 different sample 
sizes. 
DiffVar has fewer false positives in the presence of both outliers and truly 
differentially variable features 
To add complexity to the simulations we incorporated 1000 differentially variable features in 
the simulated data in addition to the 200 outliers. The variability of the 1000 CpGs in the 
second group was roughly twice that of the variability in the first group (see ‘Materials and 
Methods’). Figure 2B shows Receiver Operating Characteristic (ROC) curves for the four 
methods. It is clear that the outliers severely affect the F and Bartlett tests’ ability to detect 
the true differentially variable features. The DiffVar tests always detect more true positives 
and fewer false positives than the F and Bartlett tests, with very little difference between 
absolute or squared deviations. The dip in the curves corresponding to the F and Bartlett tests 
show that the outliers are ranked above truly differentially variable CpGs. DiffVar correctly 
ranks truly differentially variable features at the top of the list and is not affected by outliers. 
Sample size considerations for testing differential variability 
In order to accurately estimate the group variances, larger samples sizes are needed than for 
accurately estimating group means. We investigated a range of sample sizes that would 
enable reliable detection of differentially variable features. Detecting differential variability 
depends on sample size as well as how large the variability in one group is compared to the 
other. We assessed the effect of sample size for DiffVar in two ways. Firstly, through the use 
of simulations, and secondly, by subsetting the kidney cancer dataset which contains 283 
cancer tumours and 160 normal samples. 
Initially, we simulated 50,000 CpGs with 200 outliers and 5000 CpGs sites differentially 
variable between two groups with sample sizes of 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100. 
We simulated three scenarios with the 5000 differentially variable CpGs having twice, five 
times and ten times the variability in group two compared to group one, and generated 1000 
such datasets for each scenario. Total numbers of differentially variable features were 
assessed at 5% false discovery rate cut-off for the four different methods, with the numbers of 
false discoveries and true discoveries recorded for each dataset. 
In addition, we used real data from the kidney cancer versus normal tissue dataset to 
investigate the effect of sample size. We took a conservative approach to determining the 
“true” differentially variable CpGs by taking the intersection of the significant CpGs at 1% 
FDR using DiffVar (abs), the F test and the Bartlett test when analysing the full dataset. We 
randomly sampled 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 samples for each group and 
re-analysed the subsetted data in order to see how many “true” differentially variable features 
were recovered at 5% FDR. To estimate the false discovery rate, we classed any significant 
differentially variable CpG not in the list of “true” differentially variable CpGs as a false 
discovery. We repeated the sampling procedure 100 times for each distinct sample size. 
The results for the simulated and real data are displayed in Figure 2C, D, E, F and Additional 
file 2: Figure S1. Across all simulation scenarios a similar pattern emerges. While the F and 
Bartlett test tend to have greater power to detect true differentially variable CpGs, this comes 
at a price of more false discoveries, particularly at small sample sizes (Figure 2C, D, E, F and 
Additional file 2: Figure S1). DiffVar (abs) and DiffVar (sq) control the false discovery rate 
correctly at all samples sizes, however DiffVar (sq) is conservative for sample sizes below 40 
(Figure 2C, E and Additional file 2: Figure S1A, C). For data where the variability in group 
two is roughly twice that of group one, larger sample sizes are needed to detect differentially 
variable CpGs (Additional file 2: Figure S1B). For data where the variability in group two is 
roughly ten times that of group one, sample sizes as low as n = 20 show more than 80% 
power to detect differential variability (Additional file 2: Figure S1D). 
A similar story emerges when looking at the kidney cancer data. When n = 5, the Bartlett test 
is the only test to recover significant CpGs in the resampled data (Figure 2F), however it 
shows inflated false discovery rates across all sample sizes (Figure 2E). DiffVar (abs) has 
almost perfect FDR control across all sample sizes, however it lacks power when n = 5. A 
minimum sample size of 10 appears necessary to recover differentially variable CpGs (Figure 
2F). For both the simulated and real datasets we find a trade-off between control of the false 
discovery rate and power but DiffVar (abs) gives the best compromise with a lot fewer false 
positives. 
Application to TCGA methylation datasets 
Top differentially methylated and differentially variable CpG sites have little 
overlap 
We analysed the kidney, lung adenocarcinoma and prostate cancer versus normal tissue 
methylation data from TCGA (see ‘Materials and Methods’ for sample details). All samples 
were hybridised to Illumina’s Infinium HumanMethylation450 arrays. The data was read into 
R using the minfi [18] and illuminaio [38] Bioconductor packages, the raw intensities 
normalised using SWAN [39] and M values and β values calculated. Differential methylation 
was assessed by performing moderated t-statistics on the M values using the limma [17] 
Bioconductor package. Differential variability was determined using DiffVar with absolute 
deviations. Significant differentially methylated CpGs were identified as those with FDR < 
5% and difference in mean β at least 0.1. Significant differentially variable CpGs were 
identified as those having FDR < 5%, as well as having a variability ratio of at least five. In 
other words, the magnitude of the variance in one group had to be at least five times the 
magnitude of the variance in the second group. 
Under these criteria, there were 59,271 significant differentially methylated CpGs in the 
kidney cancer dataset, 77,588 in the lung cancer dataset and 71,361 in the prostate cancer 
dataset. The proportions of these that were hyper-methylated in cancer were 47% in the 
kidney cancer dataset, 47% in the lung cancer dataset and 70% in the prostate cancer dataset 
(Figure 3A). DiffVar detected 109,529 differentially variable CpGs in the kidney cancer 
dataset, 146,453 in the lung cancer dataset and 22,001 in the prostate cancer dataset (Figure 
3B), with the vast majority of these more variable in cancers compared with normal samples 
(Kidney: 99.9%, Lung: 99.8%, Prostate: 95%). 
Figure 3 Analysis of the three TCGA datasets. The top panel (A-C) shows results of CpG 
site-level analysis and the bottom panel (D-F) shows results of the CpG island-level analysis. 
Plot (A) shows the numbers of significantly differentially methylated CpG sites for the three 
cancer datasets; (B) shows the numbers of significantly differentially variable CpG sites for 
the three cancer datasets; (C) shows the overlap of the top differentially methylated and top 
differentially variable CpG sites for each cancer dataset separately. The dotted line shows the 
median overlap profile of two sets of 10,000 randomly selected CpGs. The random sampling 
was repeated 1000 times. Plot (D) shows the numbers of significant differentially methylated 
CpG islands; (E) the numbers of significant differentially variable CpG islands; and (F) 
shows a proportional venn diagram of the overlap of the top differentially variable CpG 
islands between the three different cancers. 
Restricting to only the most highly ranked significant differentially methylated and 
differentially variable CpGs, we found very little overlap between the top ranked 10,000 CpG 
sites (Figure 3C). This phenomenon was observed across all cancer datasets, with the degree 
of overlap between differentially methylated and differentially variable CpGs lower than 
expected by chance (Figure 3C). Kidney cancer had the most overlap (2%) and lung cancer 
had the least overlap (0.5%). This implies that the most significant differentially methylated 
and differentially variable CpG sites are different in the three cancer datasets analysed. 
CpG islands are highly variable in cancer samples compared to normal tissue 
samples 
We next investigated the genomic context of differentially variable probes. We found that the 
top differentially variable CpG sites were mostly in CpG islands. Furthermore there was a 
greater proportion of differentially variable sites in CpG islands compared to the 
differentially methylated CpG sites. This was consistent across the three cancer datasets 
(Figure 4A, Additional file 2: Figures S2A, S3A). An interesting observation in the kidney 
cancer dataset was that the CpG islands were over-represented among differentially variable 
CpG sites but under-represented among differentially methylated CpG sites. The lung and 
prostate cancer dataset had more CpG islands represented among the top ranked differentially 
methylated CpG sites, however there was always a greater proportion of CpG islands 
represented in the top differentially variable CpG sites. Hansen et al [9] found increased 
variability of almost all CpG sites (islands, shores and distal to islands region) in their custom 
made CHARM array. However, when analysing a publicly available colorectal cancer versus 
normal mucosa data from the Illumina Human Methylation 27 K BeadChip array they found 
that differentially variable CpGs were over-represented in sites far from islands and shores, 
and under-represented in islands. This contrasts our findings, and may be due to differences 
in the genomic region composition of the different arrays, differences in sample size (22 
matched colorectal cancer versus normal mucosa), differences in analysis strategy and 
potentially differences in tissue type. 
Figure 4 Breakdown of significant DM and DV CpG sites by genomic region in kidney 
dataset. Plot (A) shows the proportion of the top 10,000 ranked CpGs in islands, (B) open 
seas, (C) shores and (D) shelves in the kidney cancer dataset, based on UCSC annotation. 
The horizontal dashed line represents the overall proportion of probes for the genomic region 
on the array. 
This led us to examine the proportion of CpG sites in shores, shelves and open seas, based on 
UCSC annotation (Figure 4B, C, D, Additional file 2: Figures S2B, C, D, S3B, C, D). A CpG 
that is not in an island, shore or shelf was classed as being in an open sea. In the kidney 
cancer dataset there is a striking difference in the proportion of differentially methylated and 
differentially variable CpG sites in open seas (Figure 4B), with a large number of 
differentially methylated CpG sites appearing in these regions. There are fewer CpG sites in 
shelves and shores represented on the array, hence interpretation of these regions is more 
difficult. In the lung and prostate cancer datasets the differences between top differentially 
methylated and top differentially variable CpG sites in shores, shelves and open seas is not as 
striking. 
To gain additional insight in to the differentially variable and differentially methylated CpG 
sites that are in open seas, we tested whether ENCODE defined regulatory regions [40] were 
over- or under-represented (see ‘Materials and Methods’ for further details). Of the nine 
human cell types that have these regulatory regions characterised, the normal lung fibroblasts 
annotation is the only tissue relevant to any of our datasets. For the significant differentially 
variable CpGs in open seas in the lung cancer dataset we found that strong enhancers, weak 
enhancers, active promoters and weakly transcribed regions were over-represented; and 
heterochromatin/low signal regions were under-represented. For the significant differentially 
methylated CpGs in open seas, strong enhancers and active promoters were over-represented 
and heterochromatin/low signal regions were under-represented. The results are displayed in 
Additional file 3: Table S1. 
Top differentially variable CpG islands tend to differ between cancer types 
Due to the interesting finding that the differentially variable CpG sites are over-represented in 
CpG islands, we proceeded with a CpG island-level analysis by averaging the intensities of 
the CpG sites across each CpG island. Just over 30% of the probes on the array interrogate 
CpG islands, with 25,744 unique islands represented. Even though between individuals the 
CpG sites are highly variable, within an individual, the M values of the CpG sites in a CpG 
island are highly correlated (Additional file 2: Figure S4). There were 2245 significant 
differentially methylated CpG islands in the kidney dataset, 4195 in the lung dataset and 3939 
in the prostate dataset. The majority of the significant CpG islands were hyper-methylated in 
cancer compared to normal (Kidney: 92%, Lung: 87%, Prostate: 94%, Figure 3D). There 
were 4877 significant differentially variable CpG islands in the kidney dataset, 7495 in the 
lung dataset and 1745 in the prostate dataset. We found an even greater proportion of CpG 
islands were more variable in the cancers compared to the normal tissue (Kidney: 99.9%, 
Lung: 99.9%, Prostate: 98%, Figure 3E). The top 1000 differentially variable CpG islands 
showed a trend of being unmethylated in the normal samples and becoming methylated in the 
cancer samples in the Kidney dataset (Additional file 2: Figure S5). These CpG islands 
tended to differ between cancer types (Figure 3F). This agrees with the findings in Fernandez 
et al. [10], who show that the DNA methylation profile is tumour-type specific over 1054 
cancer samples, with the tumour profiles characterised by a progressive gain of methylation 
in CpG island associated promoters. In our datasets, kidney and lung cancer had the most 
differentially variable CpG islands in common (20%), but across all three cancer datasets the 
overlap was minimal (approximately 5%). 
Infiltrating cells as a cause of CpG variability between cancer samples 
One explanation of the increased variability seen in cancer samples is that cancer cells are 
frequently infiltrated with normal cells. To address this as the underlying cause of differential 
variability we performed a thorough analysis relating the methylation levels and tumour 
purity of the cancer samples in three different cancer datasets (Kidney, Lung and Uterine). 
We included an extra dataset from TCGA (Uterine corpus endometrial carcinoma) to get a 
better understanding of differentially variable CpGs that have tumour methylation signal 
explained by tumour purity in low (lung), medium (kidney) and high (uterine) tumour purity 
contexts (Figure 5A). A differential variability analysis of the Uterine dataset had 101,262 
CpGs significantly more variable in the cancer samples compared to normal samples, and 773 
CpGs significantly more variable in the normal samples compared to the cancer samples. The 
proportions of the top 10,000 differentially methylated and differentially variable CpGs in 
islands, open seas, shores and shelves was similar to the Kidney, Lung and Prostate cancer 
datasets, with a larger proportion of differentially variable CpGs in CpG islands (Additional 
file 2: Figure S6). 
Figure 5 Effect of tumour purity on methylation signal in three TCGA cancer datasets. 
Plot (A) shows the distribution of the ABSOLUTE tumour purity estimates for Uterine, 
Kidney and Lung cancer datasets. Plot (B) shows the correlation of ABSOLUTE tumour 
purity estimates with the methylation signal for the top ranked differentially variable CpG 
site in the Kidney dataset. Plot (C) shows the correlation of ABSOLUTE tumour purity 
estimates with the methylation signal for a CpG site that is classified as differentially 
variable, differentially methylated and has a large R-squared value in the Uterine cancer 
dataset. Plot (D) shows the number of CpGs that have R-squared values of at least 10% in the 
top 50,000 differentially variable CpGs. The black dashed line clearly indicates that less than 
5% of the top 50,000 differentially variable CpG sites are explained by tumour purity. 
Carter et al. [41] have developed and applied an algorithm (ABSOLUTE) to estimate tumour 
purity for a number of publicly available datasets, including 11 TCGA cancer datasets, 
although purity estimates for the prostate cancer samples are not available. There are 
ABSOLUTE estimates available for 196 samples in the Kidney cancer dataset, 236 in the 
Lung dataset and 297 samples in the Uterine cancer dataset. Figure 5A shows a density plot 
of the ABSOLUTE purity estimates for three cancer datasets: Lung (median purity = 0.44), 
Kidney (median purity = 0.56) and Uterine (median purity = 0.76). 
In order to assess the effect of tumour purity on methylation levels we fitted a linear model 
with methylation level as the response variable and tumour purity as the explanatory variable 
for the cancer samples only. The adjusted R-squared values, which can be interpreted as the 
proportion of the variation in the methylation signal that is explained by tumour purity, were 
obtained for each CpG in each cancer dataset. We classed CpGs that had an adjusted R-
squared value of greater than 10% to be the CpGs that had tumour methylation signal best 
explained by the purity of each cancer sample. For example, for the top differentially variable 
CpG in the Kidney cancer dataset, Figure 5B shows that there is no strong evidence of a 
relationship between methylation signal and tumour purity (adjusted R-squared = 0.0267). By 
contrast, Figure 5C shows the relationship for a CpG (cg08395122) that is identified as 
differentially variable (FDR = 0.0000294, Variability Ratio = 6.14), differentially methylated 
(FDR = 2e-41, Δβ = 0.3), and has a high adjusted R-squared value (0.568) in the Uterine 
cancer dataset. In the case of the CpG in Figure 5C, it is clear that the variability between 
cancer samples is mostly explained by the tumour purity. 
The numbers of CpGs on the array that had more that 10% of variability explained by purity 
were 29,424 in Kidney cancer, 47,353 in Lung cancer and 25,832 in Uterine cancer. However 
most of these were not detected as differentially variable between cancer and normal. Of the 
significant differentially variable CpGs, 3635 CpGs (3.3%) had at least 10% of the variation 
explained by tumour purity in Kidney, 14,986 (10.2%) in Lung and 2745 (2.7%) in Uterine 
cancer. Figure 5D shows the cumulative number of CpGs with at least 10% of the variation 
explained by tumour purity in the top 50,000 most significant differentially variable CpGs. 
The Lung cancer samples, which have the lowest median tumour purity, have the largest 
overlap between top differentially variable CpGs and CpGs with at least 10% of the variation 
explained by tumour purity; while the Uterine cancer samples, which have the highest median 
tumour purity, show the least overlap. 
Application to aging methylation dataset 
In order to study differential variability in aging we used data from Heyn et al. [2] to compare 
methylation in 19 centenarians to 19 newborns. We followed the same analysis strategies 
used for the cancer datasets to determine significant differentially methylated and 
differentially variable CpG sites between centenarian and newborn samples (see ‘Materials 
and Methods’). Of the 31,805 significant differentially methylated CpGs, 9130 (29%) were 
hyper-methylated in centenarians and 22,675 (71%) were hypo-methylated (Figure 6A). We 
also detected 34,680 significant differentially variable CpGs. Intriguingly, although perhaps 
unsurprisingly, 97% of these were more variable in the centenarians than in the newborns 
(Figure 6A). 
Figure 6 Analysis of aging dataset. Plot (A) shows the numbers of significant differentially 
methylated and differentially variable CpG sites and (B) shows the overlap between the top 
10,000 differentially methylated and differentially variable CpG sites. 
Comparing the 10,000 top ranked significant differentially methylated and top ranked 10,000 
differentially variable CpGs, we observed that there was less overlap than expected by chance 
(Figure 6B). Of the 31,805 total significant differentially methylated CpGs and 34,680 total 
significant differentially variable CpGs, there were 5978 CpGs in common. Of the common 
CpGs, 5842 (98%) were more variable in centenarians than newborns, with 47% hypo-
methylated and 53% hyper-methylated). 
A closer look at the genomic composition of the significant differentially methylated and 
differentially variable CpGs revealed that there were more islands and shores represented in 
the top ranked 10,000 differentially variable CpGs compared to differentially methylated 
CpGs (Additional file 2: Figure S7A, C). There were more CpGs in open seas and shelves in 
the top differentially methylated CpGs than in the top differentially variable CpGs 
(Additional file 2: Figure S7B, D). 
The CpGs that were significantly more variable in the centenarians compared to newborns 
corresponded to 7068 genes and the CpG sites that were more variable in newborns compared 
to centenarians corresponded to 484 genes (UCSC annotation). We performed a GOstats 
analysis [42] testing for over-representation of GO terms amongst the genes associated with 
differentially variable CpGs. For the CpGs that are more variable in centenarians compared to 
newborns, many GO categories relating to development were significant (Additional file 4: 
Table S2, p-value cut-off = 0.0001). Far fewer GO terms were significant when testing the 
genes associated with CpGs that were more variable in newborns compared to centenarians; 
however several GO terms related to MHC protein complex were significant, as well as a 
leukocyte mediated immunity GO term (Additional file 4: Table S2). 
Discussion 
In this paper we present DiffVar, a new method to detect differential variability between 
groups of samples. DiffVar is freely available as an R function in the missMethyl 
Bioconductor package. Our test is based on Levene’s z-test for variances and incorporates an 
empirical Bayes modelling framework to appropriately deal with high dimensional data 
issues. We find the test holds its size, is robust to outliers and outperforms the F and Bartlett 
test in terms of controlling the false discovery rate. For smaller sample sizes, the F and 
Bartlett test are more powerful; however this comes at a price of higher false discovery rates. 
DiffVar with absolute deviations represents the best compromise between controlling the 
FDR and power to detect differential variability. 
In order to reliably estimate the variance of a group, more observations are needed than for 
estimating a mean. We found that for group sizes as low as 10 in the kidney cancer dataset 
there was adequate power to detect differential variability, with the power increasing 
dramatically up to group sizes of 50 arrays. However, detection of differential variability is 
also dependent on how large the variability in one group is relative to the other. In addition to 
a false discovery rate cut-off, one can specify a threshold on the variability ratio, which is the 
ratio of the variance in one group compared to the variance in the second group. For example, 
when analysing the cancer and aging datasets, in addition to the FDR cut-off of 5%, we 
required a variability ratio of at least five between the two groups for a CpG to be called 
significantly differentially variable. 
We applied our differential variability testing method to several cancer data sets from TCGA 
as well as a publicly available aging dataset. For the cancer datasets, we found that a large 
proportion of sites showed differential variability and, as expected, were more variable in 
cancer compared with normal tissue. For the aging dataset, we found that a large proportion 
of CpG sites were more variable in centenarians than newborns. Interestingly, for the top 
ranked CpGs in both the cancer and aging datasets, the overlap between differentially 
variable and differentially methylated CpGs was less than expected by chance. 
In all cancer datasets we showed that CpG islands were enriched for differential variability. 
This is important because methylation of CpG islands in cancer cells is known to contribute 
to gene silencing [43]. CpG sites that are differentially variable may reflect a loss of 
epigenetic control that could be contributing to tumourigenesis. Another hypothesis is that 
differentially variable CpG sites capture the heterogeneity between patients whose tumours 
arose due to the disruption or activation of different biological pathways. For some cancer 
patients, the methylation status of a differentially variable CpG site is similar to the 
methylation status in a normal cohort, while for other patients the same CpG site shows 
aberrant methylation. This type of analysis has the potential to be used as a starting point to 
identify clusters of patients whose tumours arose via similar molecular mechanisms. For the 
cancer datasets analysed in this paper, we found that only a small proportion of differentially 
variable CpGs could be explained by tumour purity. 
In this paper we have focused on DNA methylation data that has been generated using 
Illumina’s Infinium HumanMethylation450 BeadChip. DiffVar can also be applied to DNA 
methylation sequencing data or any set of β or M values from CpG sites or regions. The 
DiffVar function will transform a matrix of β values into M values by applying a logit 
transformation. In general, the DiffVar method for testing differential variability can be 
applied to any ‘omics data which uses the limma pipeline for analysis, such as microarray 
expression data or RNA-seq data. For RNA-Seq data, DiffVar will perform a voom 
transformation [44] before testing for differential variability. The DiffVar modelling 
framework has the added benefit of giving the user access to other tools in the limma 
package, for example, testing relative to a threshold (TREAT [45]), as well as gene set testing 
functions ROAST [46] and CAMERA [47]. 
Conclusions 
DiffVar is a novel method to test for differential variability in high-throughput genomics data 
such as methylation arrays or gene expression data. We have shown that DiffVar controls the 
false discovery rate while being robust to outliers. DiffVar is available as an R function in the 
missMethyl Bioconductor package. 
Materials and methods 
Illumina Infinium HumanMethylation450 beadchip 
The Illumina Infinium HumanMethylation450 beadchip allows for the simultaneous 
measurement of 482,421 CpG sites. There are two types of probes: Infinium I, which were 
previously used on the Infinium HumanMethylation27 array and constitute 135,501 probes; 
and Infinium II, which make up the rest of the probes. The Infinium I design has two probes 
which measure the methylated and unmethylated state respectively, whereas the Infinium II 
design has a single probe which can detect whether a CpG site is methylated or unmethylated. 
A thorough description of the array design is available in Maksimovic et al. [39]. The 
resulting data is similar to two-colour microarray gene expression data; there is an intensity 
measurement for both the methylated and unmethylated channel for each CpG site. The main 
difference is that the dynamic range for expression data is different to the dynamic range for 
methylation data. SWAN normalisation can be performed on the Infinium I and Infinium II 
probes within each array to reduce the technical biases inherent in the probe design before 
statistical analysis [39]. Once normalisation has been performed, β values for each CpG site 
can be computed as the ratio of the methylated intensity versus the combined methylated plus 
unmethylated intensity. Du et al. [34] recommend the use of M values for statistical analysis, 
which are calculated as the log2-ratio of methylated versus unmethylated intensities. A small 
offset can be added to the numerator and denominator to stabilise the M values. M values 
with an offset of 100 to both the numerator and denominator are used in all statistical 
analyses reported in this paper. 
Datasets 
Throughout the paper we demonstrate our method with publicly available datasets generated 
by The Cancer Genome Atlas (TCGA) Research Network [48], as well as an aging dataset, 
all of which have methylation profiled using the Illumina HumanMethylation450 arrays. In 
all TCGA datasets used, the cancer samples are from solid tumours and the normal samples 
are from solid normal tissue. The raw data in the form of idat files (called “Level 1” data on 
the TCGA website) for the “Methylation450” platform were downloaded from the TCGA 
data portal [49] and sample annotation was downloaded from the Biospecimen Metadata 
Browser [50] by specifying “Analyte” as the element and “DNA” as the analyte. The clear 
cell kidney carcinoma versus normal tissue dataset (KIRC) has 160 normal samples and 283 
cancer samples. The lung adenocarcinoma dataset (LUAD) has 427 cancer samples and 31 
normal samples. The prostate adenocarcinoma (PRAD) has 194 cancer samples and 49 
normal samples. The uterine corpus endometrial carcinoma dataset (UCEC) has 423 cancer 
samples and 34 normal samples. The specific sample identifiers and other sample information 
can be found in Additional file 5: Table S3, Additional file 6: Table S4, Additional file 7: 
Table S5 and Additional file 8: Table S6. For the aging dataset, methylation profiles were 
generated from 19 healthy male centenarian peripheral blood samples and 19 male newborn 
umbilical cord blood samples. The data is available for download from the Gene Expression 
Omnibus (series accession number GSE30870). 
Data analysis 
The data was read into R from raw idat files using the minfi [18] and illuminaio [38] 
packages. For the cancer datasets, CpG sites on the X and Y chromosomes were filtered out. 
An additional filter was applied to all datasets where CpG sites that had a detection p-value of 
greater than 0.01 in one or more samples were excluded from further analysis. This resulted 
in 445,378 CpG sites for the kidney cancer analysis, 419,031 CpG sites for the lung cancer 
analysis, 448,145 CpG sites for the prostate cancer analysis, 421,795 CpG sites for the uterine 
cancer analysis and 483,615 CpG sites for the aging analysis. The raw intensities were 
SWAN normalised [39], and finally β and M values extracted. Statistical analysis was 
performed on the M values. Differentially methylated CpG sites were determined using 
moderated t statistics from the limma package [17]. Significant differentially methylated 
CpGs were defined as having false discovery rate (FDR) of less than 5% and a difference in 
mean beta level of at least 0.1 between the two groups. Differential variability was assessed 
using DiffVar with absolute deviations from the missMethyl package. Significant 
differentially variable CpGs were defined as having FDR less than 5% and a ratio of group 
variances of at least 5. Testing for enrichment of GO categories in the aging dataset was 
performed using the R GOstats package [42]. The R code for the analysis is available in 
Additional file 9. The tables of significant differentially methylated and differentially variable 
CpGs are available from the authors on request. 
Simulations 
To check the performance of our method we generated datasets where the truth is known in 
order to gain insight into Type I error rate and false discovery rate control. Data was 
generated under a hierarchical model whereby the variance for each CpG was first sampled 
from an inverse chi-square distribution and the M value for each CpG was sampled from a 
normal distribution with variance equal to the simulated variance. A two group problem with 
50 arrays in each group and ten thousand CpGs were generated in this manner. One thousand 
datasets with no differential variability were simulated by first sampling variances for each 
CpG site from a scaled inverse chi-square distribution with scaling factor d0 s0
2
 and degrees 
of freedom d0 such that the two groups have equal variance. We chose d0 = 20, which 
represents the scenario where the observed variances are shrunk 20/(50 + 20) = 0.29 towards 
the prior variance. In other words, more weight is placed on the observed variance during the 
empirical Bayes shrinkage step. We chose s0
2
 = 0.64, which is slightly more variable than the 
hyper-parameter estimates obtained when analysing the larger TCGA cancer datasets 
(Kidney: 0.26, Lung: 0.11, Prostate: 0.16). The M values were generated to mimic 
methylation data by randomly sampling half the CpGs from a normal distribution with mean 
equal to -2 and variance equal to the sampled variance for the unmethylated CpGs; and the 
remainder representing methylated CpGs had M-values sampled from a normal distribution 
with mean equal to 2 and variance equal to the sampled variance. The range of M values this 
simulation scenario produced is shown in Additional file 2: Figure S8A. 
Type I error rates were also assessed using the M values of the non-diseased samples from 
the kidney cancer dataset. One thousand datasets were generated by first randomly sampling 
ten thousand of the 445,378 CpGs, followed by randomly selecting 100 normal samples, of 
which 50 were allocated to the “normal” group and 50 were allocated to the “cancer” group. 
Theoretically, for each CpG the two groups should have equal variance, although additional 
factors such inter-individual heterogeneity will make the data more variable. The sampling 
strategy should preserve any correlation structure between the CpG sites. The range of M 
values this produced for one such dataset is shown in Additional file 2: Figure S8B. 
To assess the impact of outliers we modified the simulations to include outliers for 200 CpG 
sites. For each of these 200 CpGs the M-value for one simulated sample was replaced with 
the maximum simulated M value over all ten thousand CpGs. We introduced differential 
variability for another 1000 CpGs by simulating larger variances for one of the groups by 
sampling from a scaled inverse chi-square distribution with scaling factor d0 s0
2
 and degrees 
of freedom d0, where d0 = 20 and s0
2
 = 1.5. On average, the variability of the 1000 CpGs in 
the second group is 1.5/0.64 = 2.34 times larger than the variability in the first group. 
Differential variability was assessed using our method DiffVar, the F test for equality of 
variances and the Bartlett test. All three tests had two-sided p-values computed. Type I error 
rates and false discovery rates were calculated and averaged over the 1000 simulations in 
each simulation scenario. 
The simulations to assess the effect of sample size were modified slightly by increasing the 
numbers of simulated CpGs to 50,000 and allowing 5000 CpGs to be differentially variable. 
Three different levels of variability were considered: group two roughly twice, five times and 
ten times more variable than group one. A two group problem with varying sample size (n = 
10, 20, 30, 40, 50, 60, 70, 80, 90, 100) was simulated with 1000 datasets generated for each 
distinct sample size. The numbers of truly differentially variable CpGs recovered at a 5% 
FDR and the numbers of false discoveries was recorded for each sample size. Additional file 
10 shows the R code for the simulations. For the sub-setting and resampling of the kidney 
cancer dataset we defined a set of true positives and true negatives in the following way. CpG 
sites that were differentially variable at 1% FDR using DiffVar (abs), the Bartlett and F test 
when analysing the full dataset were classed as true positives. All other CpG sites were 
classed as true negatives. The false discovery rate for each sub-setted dataset was estimated 
by counting the number of true negatives that were significantly differentially variable and 
dividing by the total number of significant differentially variable CpG sites at a 5% FDR cut-
off. Power for each sub-setted dataset was calculated by counting the number of true 
positives that were significantly differentially variable at 5% FDR and dividing by the total 
number of true positives. 
Overlap analysis of ENCODE regulatory regions 
Ernst et al. [40] used a Hidden Markov Model to segment the genome and computationally 
predict functional elements for nine human cell types, using ChIP-Seq data for nine factors 
plus input. The chromatin state segmentation annotation is available for download at the 
ENCODE website [51]. The only relevant tissue where annotation is available is for normal 
lung fibroblasts. We determined whether CpG sites that were significantly differentially 
variable and in open seas (as opposed to islands, shores and shelves) lay in regions that have 
predicted functional elements using an intersectBed analysis in the Lung cancer dataset. We 
calculated the total number of each functional element represented on the array by taking all 
CpGs in open seas and performing an intersectBed analysis. We then calculated the 
probability of each functional element being over- or under-represented in the list of 
significant differentially variable and differentially methylated CpGs separately using a 
hypergeometric test. The p-values were adjusted for multiple testing using Holm’s method 
[52]. 
Infiltrating cells analysis 
ABSOLUTE tumour purity estimates for the Kidney, Lung and Uterine cancer datasets were 
downloaded from the Synapse website [53]. Adjusted R-squared values were used to 
determine the proportion of variation in the tumour methylation signal explained by the 
tumour sample purity. Adjusted R-squared values were extracted from a linear model fit, 
regressing the methylation signal on the ABSOLUTE tumour sample purity estimates of the 
cancer samples for all CpG sites. This was performed in R using the lm function. CpG sites 
that had adjusted R-squared values of more than 10% were classed as CpGs that had 
methylation signal explained by tumour purity. 
missMethyl Bioconductor package 
The DiffVar method is currently available from Bioconductor in the development version of 
the missMethyl package [54]. Following the next release of Bioconductor (version 3.0), 
scheduled for 14 October 2014, DiffVar will be available in the release version of the 
missMethyl package [55]. 
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